

Review Article

Tissue-Engineered Subretinal Implants Restore High-Resolution Vision in AMD and RP

Mohamad Negahi¹, Alireza Mofakhami Pourmehrabadi¹, Saeedeh Hajihosseini², Bibi Fatemeh Haghiralsadat², Fatemeh Kuchakzade^{3,4*}

1- NanoBiotechnologists Fardanegar Co., Yazd Science and Technology Park, Yazd, Iran.

2- Stem Cell Biology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

3- Biotechnology Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

4- Tissue Engineering and Applied Cell Sciences Department, School of Advanced Medical Technologies, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

*Corresponding Author:

Kuchakzade, Fatemeh

Email:

Fatemehkuchakzade@gmail.com

Received:

2026-04-04

Accepted:

2026-06-10

Volume:2

Issue no.1

Editor-in-Chief:

Behrouz Aflatoonian Ph.D.



Copyright © 2025 The Authors.

This work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Age-related macular degeneration and retinitis pigmentosa represent the leading causes of permanent blindness globally, now affecting more than 200 million people as of 2026, a burden that weighs heavily on healthcare systems and families alike. The Argus II and PRIMA implants, which operate through retinal surface contact, fail to provide significant visual results because their limited electrode distribution (under 100 contacts for Argus II, 378 for PRIMA) can only produce visual output matching 20/1260 acuity at maximum. This limitation arises from their design, which activates ganglion cells instead of targeting the retinal inner layers. Over the past several years, researchers have shown that hydrogels such as gelatin methacryloyl and hyaluronic acid can maintain lab-grown retinal pigment epithelium cells from patients' own reprogrammed stem cells alive and functioning for over one year. These cells form tight barriers (electrical resistance across them exceeds $300 \Omega \cdot \text{cm}^2$) and respond to light in ways confirmed by sensitive electrode recordings. In preclinical porcine models, whose eyes closely resemble human eyes in size, vision improvements of 20-30% on motion tests have been demonstrated, with better preservation of the light-sensing cell layer. Smart drug-releasing coatings further help by reducing scar tissue buildup to under 15%. The research pathway from laboratories to clinical applications requires standardized cell production followed by safety testing in limited volunteer cohorts, leading to trials that demonstrate actual improvements in vision. If successfully developed and scaled, these implants could potentially reduce the treatment burden compared to current wet AMD management methods that require patients to receive frequent injections. This approach represents a paradigm shift in vision loss management by establishing methods to both prevent vision loss and restore lost vision.

Keywords: AMD, Hydrogels, IPSC-derived RPE, Subretinal implant, Tissue engineering

How to cite this article:

Negahi, M., Mofakhami Pourmehrabadi, A., Hajihosseini, S., Haghiralsadat, F., Kouchakzade, F. Tissue-Engineered Subretinal Implants Restore High-Resolution Vision in AMD and RP. *Regenerative Biomedicine*, 2025; 2(1): 82-105. <https://doi.org/10.22034/jrb.2026.07.V2I1A6>



Introduction

Diseases like age-related macular degeneration (AMD) and retinitis pigmentosa (RP) drive most cases of irreversible blindness in adults and older people around the world. Recent studies estimate affected patients at over 200 million globally in 2026, with healthcare costs running into tens of billions yearly across major economies (1,2). AMD causes roughly 70% of legal blindness past age 65, while RP strikes younger individuals, peaking between ages 20-40 (2,3).

Clinical Burden and Unmet Needs

AMD splits into dry (85-90% of cases) and wet (10-15%), both affecting the outer retina substantially (4). Dry AMD builds up drusen under RPE cells, progressing to geographic atrophy that eliminates RPE sheets and photoreceptors, now affecting 5-10 million North Americans (5). Wet AMD sparks choroidal vessel overgrowth where 40% of untreated cases scar within two years; anti-VEGF shots stabilize 90% structurally but only 30% gain over 15 letters on vision charts (6). Geographic atrophy recently gained complement C3/C5 blockers slowing growth 27-30% over two years, though this represents modest benefit (7,8). RP progresses through rods then cones, leaving 90% legally blind by age 40 (7). Unlike AMD's macular focus, RP affects mid-peripheral retina first, causing light hypersensitivity while preserving foveal islands until late stages (8). Luxturna gene therapy reaches under 1% of recessive cases, leaving 99% of RP patients without disease-modifying treatments (9).

Current Prosthetic Limitations

Epiretinal devices, Argus II (96 electrodes, 60 μm apart) and PRIMA (378 electrodes, achieving 20/1260 vision), bypass degenerated photoreceptors to stimulate ganglion cells directly (10). Argus II received FDA approval in 2013 for end-stage RP/Usher syndrome but demonstrated limited long-term success: 42% explanation within four years from conjunctival erosion, 7% infections, and electrode failures (11). PRIMA's IR microLEDs achieve tighter pixel packing, but ganglion field sizes (200-500 μm) limit acuity under 20/200 regardless of electrode density. Center-surround receptive field wiring blocks sharp vision, and misplaced stimulation distorts brain phosphene maps. Patients achieve 70% object spotting and 55% motion direction discrimination, adequate for basic navigation but insufficient for reading at 20+ words/minute or face recognition required for vocational activities (10).

Subretinal Tissue Engineering Paradigm

Subretinal implants position adjacent to surviving inner retinal layers for direct photoreceptor and bipolar cell activation via intact retinal wiring (12). This configuration eliminates suprachoroidal instability observed with epiretinal devices, with natural internal limiting membrane grip and vitreous support maintaining migration rates below 5% in animal models (13). Alpha-IMS/AMS trials (11 electrodes, 1.5 mm^2) achieved pattern recognition at 20/546 in late RP patients, demonstrating 3-5 $\times$ sharper phosphenes than surface technologies (14). Tissue-engineered versions layer cells onto scaffolds addressing RPE gaps, photoreceptor support, and synapse loss (15).

GelMA/hyaluronic acid hydrogels match Bruch's membrane flexibility (0.5-5 MPa) while enabling sustained delivery of VEGF/PEDF, CNTF/BDNF, and rapamycin (16). iPSC-RPE sheets achieve $>300 \Omega\cdot\text{cm}^2$ barrier resistance with appropriate PEDF secretion and phagocytic function matching native tissue, demonstrated in year-long porcine grafts (15,17). Biohybrid systems fuse cells to microLEDs ($10\times 10 \mu\text{m}$) with optogenetic ChR2 expression in bipolar cells, achieving $1000\times$ higher density than photovoltaic approaches (18). Multielectrode arrays capture natural light response timing (50-80 ms peaks), demonstrating 2-3 log superior contrast compared to existing technologies (10,19).

Translational Rationale and Review Scope

Preclinical studies in Yucatan pigs demonstrate 25% motion vision rescue with outer nuclear layer preservation at 18 months; primate electroretinograms confirm synaptic strength surpassing flat cell sheets (20). Sustained rapamycin delivery reduces scarring to 12%, comparable to subretinal drug administration (21). This review examines scaffold materials, cellular engineering strategies, surgical delivery innovations, cell-electronic integration, and regulatory pathways toward clinical trials, synthesizing 2020-2026 research from ophthalmology, materials science, and neural engineering demonstrating the subretinal approach toward functional 20/200 vision restoration (22). This review is structured as follows: Section 2 examines scaffold materials including hydrogels and nanostructured platforms; Section 3 addresses cell sources and differentiation protocols; Section 4

explores biohybrid cell-chip integration; Section 5 discusses surgical delivery systems; Section 6 presents preclinical outcomes and current limitations; Section 7 outlines the clinical translation roadmap; and Section 8 identifies future directions in the field.

Scaffold Materials for Subretinal Implants

Subretinal scaffolds must replicate both the mechanical properties and chemistry of Bruch's membrane while supporting cells long-term and accommodating small-caliber surgical instruments (23). Native Bruch's membrane is a thin, multilayer structure with basement membrane, elastic, and collagenous components exhibiting modulus approximately 1 MPa; recent synthetic PEG-based systems have been tuned to 0.3-5 MPa range with high optical transmission across visible wavelengths (24,25).

Hydrogel Systems

Hydrogels offer advantages through high water content and diffusivity replicating hydrated extracellular matrix and enabling adequate oxygen supply to avascular retinal pigment epithelium (26). Gelatin-based methacrylated hydrogels such as GelMA crosslink with long-wavelength UV or visible light at low intensities and can be engineered for degradation over several months, providing temporary support during transplanted cell integration (27). Research on gelatin-hyaluronic acid interpenetrating networks demonstrates these matrices enable human retinal cell growth in laboratory and living systems while preserving barrier function and enhancing host integration (28). Injectable hyaluronic acid (HA) derivatives provide utility through shear-thinning and

stress-relaxation properties enabling gel injection through narrow needles while maintaining stable subretinal or vitreous positioning (29). The low kilopascal stiffness range of HA-based hydrogels has allowed RPE and retinal progenitor cell survival and improved integration in rodent and porcine models through reduced oxidative stress and improved retinal surface adhesion compared to stiffer synthetic networks (30). HA-CD44 interactions on microglia and immune cells minimize inflammatory responses, providing benefit for long-term implant retention (31). Poly(ethylene glycol) (PEG) systems enable independent control of ligand density (e.g., RGD) and crosslinking chemistry, allowing manipulation of cell adhesion and stiffness as separate parameters (32). PEG-based hydrogels matching Bruch's membrane elastic properties for RPE culture demonstrate that scaffold stiffness affects cell survival and tight-junction and RPE-specific marker expression (33,34). Enzymatic and non-photoinitiated crosslinking methods avoid UV exposure risks to light-sensitive retinal cells (35). Combining natural and synthetic networks in dual or interpenetrating systems yields hybrid mechanical behavior and refined spatial patterning. Gelatin-HA or gellan gum-HA hydrogels provide appropriate support and stress relaxation, improving RPE or human retinal progenitor cell spreading and barrier recovery after injury in vitro and in vivo (28). Such systems show promise for subretinal delivery where mechanical robustness during surgery must balance with controlled degradation afterward (36).

Nanostructured Scaffolds

Introducing nanoscale topography helps recreate outer retinal organization and guide cell alignment and polarization (37). Electrospun nanofibers from polymers like PLGA or fibroin mimic Bruch's membrane and support RPE growth, forming fibrous components of bilayer constructs including vascular-like hydrogel underlayers (38). Patterned nanofibrous mats encourage proper RPE morphology and improve interactions with endothelial cells in choroid-mimicking structures (39).

Conductive nanocomposites, such as carbon nanotubes (CNTs) combined with biodegradable polymers, add electrical functionality without complete light blockage (40). CNT-polymer composites demonstrate enhanced conductivity, good biocompatibility, and improved survival and differentiation of retinal neurons and retinal ganglion cell-like cells compared with polymer alone (41). These properties make them attractive for coupling cell-based implants with prosthetic stimulation or modulating local electric fields during integration (40,41). Graphene oxide (GO)-based coatings and hydrogels have been explored for retinal prostheses (42,43). GO offers high surface area, favorable charge-storage characteristics, and can be combined with hydrogels to improve cell attachment, charge transfer, and drug delivery at electrode-tissue interfaces. In vitro and in vivo studies indicate GO-containing materials can reduce inflammatory activation and improve neuronal process outgrowth, suggesting roles in stabilizing subretinal tissue-device contacts (42).

Long-term Safety and Translational Challenges of Nanomaterials

While carbon nanotubes and graphene oxide offer promising conductive properties for retinal scaffolds, their long-term safety profiles require careful consideration. Multi-walled carbon nanotubes (MWCNTs) have demonstrated potential for oxidative stress induction and granuloma formation in pulmonary studies, though subretinal application limits systemic exposure (40,41). The biodegradation pathways for CNTs in the subretinal space remain incompletely characterized, with persistence beyond scaffold degradation timelines raising concerns for chronic inflammation (40).

Graphene oxide biocompatibility depends critically on oxidation degree and flake size. Reduced GO (rGO) shows improved conductivity but reduced hydrophilicity, potentially compromising long-term integration with host tissue (42). The blood-retina barrier may limit clearance of nanoscale debris, necessitating thorough toxicological evaluation in large animal models exceeding 2-year follow-up periods (158). Regulatory pathways for nanomaterial-containing implants remain under development. The FDA has issued guidance on nanotechnology-based medical products, emphasizing the need for characterization of physicochemical properties, in vivo fate, and potential for long-term accumulation (167). European Medicines Agency guidelines similarly require extensive biodistribution studies for nanomaterial-based therapeutics. Translation to clinical use will require demonstration of complete scaffold biodegradation or safe long-term retention, with comprehensive monitoring for delayed inflammatory responses.

Drug Delivery Integration

Integrating controlled drug release into subretinal scaffolds supports transplanted cells and conditions host retina (44). Neurotrophin-eluting hydrogels, originally developed for tissue-electrode interfaces in retinal prostheses, deliver molecules such as BDNF to promote neuron survival and neurite extension in retinal explants (45). Similar approaches can be adapted to subretinal tissue-engineering matrices to maintain photoreceptor and bipolar cells during vulnerable post-implantation periods (46).

Hydrogel or fiber-based systems tune pro- and anti-angiogenic factor release, for example by balancing VEGF and pigment epithelium-derived factor (PEDF), to preserve choriocapillaris function without triggering neovascularization (47). Recent biomimetic Bruch's membrane models and engineered microstructured materials highlight how local presentation of growth factors and inhibitors within Bruch's membrane-like scaffolds influences RPE behavior and vascular responses in AMD models (38). Nanoparticle carriers embedded within hydrogels have been proposed for sustained delivery of anti-fibrotic or anti-inflammatory agents to limit scarring around subretinal devices (48).

Fabrication Advances

Advances in micro- and nanofabrication expand design possibilities for Bruch's-membrane-like scaffolds (49). Photolithography and microfabrication pattern methacrylated HA hydrogels with microchannels mimicking choroidal vascular trees, combined with electrospun nanofiber layers supporting RPE growth, yielding bilayer constructs recapitulating key outer

retinal structural aspects (50). Stereolithography and related 3D printing techniques generate thin, mechanically tunable PEG-based membranes with microstructured features and moduli similar to native Bruch's membrane (49-51).

Cryogelation and porogen-based methods create macroporous hydrogels with high void fractions and good toughness, serving as artificial basement membranes for RPE or stem-cell-derived retinal cells while tolerating surgical manipulation (50). Injectable GG/HA cryogels demonstrate that appropriate pore architecture and stress-relaxation behavior are critical for engraftment and barrier formation (52). Lyophilized, rehydratable smart scaffolds that expand rapidly in situ illustrate how preformed structures can be delivered through narrow cannulas and re-form conformal sheets under the retina, potentially simplifying surgery (53,54).

Cell Sources & Differentiation

Living cells in subretinal implants provide actual functionality, requiring both physical integration into retina and restoration of outer retinal light signaling (55). Cells derived from induced pluripotent stem cells (iPSCs) have become preferred because they can be expanded in quantity, matched for immune compatibility, and even carry patient-specific disease traits for testing (56).

RPE Monolayers

Protocols for iPSC-to-RPE differentiation now routinely produce over 95% cells expressing key markers like MITF and BEST1 in 6-8 weeks without animal products (57,58). Early SMAD signaling blockade (SB431542 and LDN193189) followed by

timed GSK3 β and HDAC pathway activation creates uniform, pigmented sheets with microvilli and appropriate sodium pump polarization (59,60). These cells achieve barrier strength above 350 Ω -cm² by week 6, demonstrate anion currents through bestrophin channels, and secrete VEGF and PEDF in ratios matching native RPE (61).

Phagocytosis (daily photoreceptor outer segment clearance) reaches levels comparable to fresh human RPE, processing thousands of segments per cell with lysosome fusion on appropriate schedules (62). Rod protein breakdown follows native kinetics through standard autophagy pathways, confirmed in short-term co-culture with photoreceptors, and these cells secrete complement factor H at rates blocking inflammation 3-fold better than fibroblast controls (63).

Genetic analysis shows near-perfect chromosome stability even after extended passage, enabling correction of AMD-linked variants like CFH Y402H or ARMS2 A69S back to wild-type (64-66). Corrected patient cells regain nearly full phagocytic function, demonstrating these modifications can rescue disease phenotypes for autologous transplantation (67,68). Long-term subretinal RPE sheet transplants in large animal models demonstrate high graft survival (>80%) with sustained RPE65 expression over extended areas, accompanied by choroidal revascularization and improved photoreceptor layer preservation compared to dissociated cell suspensions (69,70).

Photoreceptor Precursors

Rod precursors emerge at 20-25% from iPSC retinal organoids through Notch inhibition (DAPT at weeks 6-8) and late thyroid hormone addition (68). Markers like CRX

and NR2E3 peak by day 85 in over 40% of cells, producing recoverin- and rhodopsin-positive rods with segment-like extensions 8-12 μm long, plus 12-15% cones matching foveal edge composition (71). iPSC-derived photoreceptors generate light-evoked responses (~ 100 μV) detectable by microelectrode arrays with physiological timing, while co-culture studies demonstrate functional glutamate release to bipolar cells confirming synaptic connectivity (72,73).

Electron microscopy confirms ribbon synapse formation in iPSC-derived retinal organoids, revealing native-like presynaptic ribbon structures and precise alignment with postsynaptic bipolar cell processes (74). Mouse models demonstrate long-term survival of transplanted photoreceptor precursors (up to 6 months) with functional integration into host retinal layers and partial dim-light vision restoration, while humanized mouse studies confirm correction of patient-derived opsin trafficking defects (75).

Cellular Coculture Optimization

Co-culture of photoreceptor precursors with RPE cells enhances precursor survival and maturation through reciprocal trophic signaling, with RPE-conditioned media upregulating growth factor receptors and photoreceptors stabilizing RPE barrier function (76). Endothelial co-cultures with retinal organoids establish vascular networks enhancing RPE oxygenation and reducing pathological angiogenesis, addressing limitations of avascular organoid models (75). Müller glia co-culture reduces gliosis-mediated scarring and preserves photoreceptor layer thickness while maintaining native rod/cone ratios over extended culture periods (77).

Genetic Engineering Enhancements

Expression of stabilized Channelrhodopsin-2 (ChR2) in bipolar cells generates robust blue light-evoked currents (~ 400 -500 pA) with high-frequency response capabilities up to 40 Hz, mimicking cone photoreceptor temporal properties (78). Dual opsin expression enables spectrally opponent push-pull retinal signaling, while CRISPR activation of rod-specific genes enhances photoreceptor commitment and P23H opsin trafficking corrections restore near-native light responses in patient-derived cells (75). Gene delivery systems maintain sustained BDNF expression for up to 6 months and prolong cone survival factors significantly in mouse models of retinal degeneration (76).

Manufacturing Scale-Up

Nanofiber scaffolds enable long-term RPE culture (up to 12 months) with stable cell density, morphology, and polarization, demonstrating suitability as transplantation substrates (79). Optimized dissociation protocols achieve $>90\%$ RPE cell viability with preserved morphology, while animal-free media maintain genomic stability ($<0.5\%$ aneuploidy) across multiple passages (80,81). Photoreceptor precursors demonstrate 87% post-thaw viability using cryoprotectant stabilizers while maintaining 92% expression of characteristic differentiation markers (82). A haplobank of ~ 1500 HLA-homozygous iPSC lines provides extensive population coverage for European patients, significantly reducing HLA mismatch rates compared to heterozygous donor pools (83).

Biohybrid Retinal Implants: Cells Meet Chips

Biohybrid implants utilize living retinal cells combined with miniature electronic devices to replace missing photoreceptors and generate artificial light signals simultaneously (84). This approach enables improved performance by combining biological and electronic functions working through both natural processes and engineered systems (85,86).

Optogenetic Enhancement

Channelrhodopsin-2 (ChR2) variants restore light sensitivity to surviving bipolar cells through robust photocurrents (~600-700 pA) evoked by blue light stimulation (470 nm), enabling physiological retinal signaling (78). H134R Channelrhodopsin variants prolong channel open times to better match rod photoreceptor temporal dynamics, while CatCh variants shift spectral sensitivity toward green wavelengths for improved activation under ambient lighting (78,87). Step-function Channelrhodopsins like ChIEF maintain stable photocurrents through extensive activation cycles, enabling reliable long-term operation (88).

Chloride pumps like GtACR1 enable yellow light hyperpolarization of OFF cells, doubling contrast by engaging ON and OFF pathways simultaneously (89).

Halorhodopsin (NpHR3.0) pairing with Channelrhodopsin variants achieves >6 orders of magnitude dynamic range, spanning scotopic to photopic brightness levels (90,91). Multielectrode array recordings demonstrate that optogenetic photoreceptor stimulation drives vesicular glutamate release with paired-pulse depression characteristics and evokes postsynaptic responses with millisecond-scale latencies, confirming functional ribbon

synapse transmission and preserved retinal microcircuit function (92,93). AAV capsid variants achieve >90% transduction efficiency across large retinal areas, with porcine studies demonstrating sustained transgene expression (~75-80%) at 9 months and favorable immune profiles (94-96).

MicroLED Integration

Gallium nitride microLED arrays with 5-20 μm pixels achieve ultra-high brightness ($>10^7$ cd/m^2), high contrast ratios (10,000:1-100,000:1), and 60 Hz refresh rates, demonstrating significantly greater efficiency, brightness, and durability than organic LEDs for optogenetic applications (97,98). High-density gallium nitride microLED arrays with 5 μm pixels (3400 PPI) achieve ultra-high brightness for retinal prosthesis applications, while liquid-encapsulated quantum dot color conversion films demonstrate 90% stability maintenance under accelerated aging (97,99). Thin-film polyimide microelectrode arrays conform to retinal curvature for epiretinal implantation, while atomic layer deposited Al_2O_3 and parylene C bilayer encapsulation maintains high impedance (3.5 $\text{M}\Omega$) and stable wireless performance over 1000+ days of accelerated aging, supporting chronic neural interfaces with inductive power transfer efficiencies up to 95% (100-102).

Synaptic Circuitry Engineering

Lab-grown photoreceptors form synaptic ribbons matching host bipolar cells in 84% of cases within two months, releasing vesicles and glutamate akin to native cells with 73% receptor occupancy (103). ECM guides like laminin favor bipolar connections 3.4-fold, laminin islands cluster dendrites, and netrin enhances ON pathway targeting to 91% (104).

Blockade of Cx36-containing gap junctions with meclofenamic acid eliminates aberrant oscillatory activity in degenerating retina and restores light sensitivity, improving signal fidelity for electrical stimulation (105,106).

Closed-Loop Systems

Tiny CMOS sensors (3 μm pixels) process images onboard, reducing data needs by 85% while neural nets detect motion at 92% accuracy with natural spike timing. Machine learning tunes phosphenes in three trials, raising letter identification from 42% to 78% alongside 2.3-fold brain activation (107). CMOS image sensors with integrated spatial processing units and light-controlled oscillating pixels enable onboard image processing for optobionic systems, achieving dynamic ranges of 143dB and oscillation frequencies from 0.24Hz to 2.2kHz (108).

Power and Thermal Management

Piezoelectric films harvest mechanical energy from ocular movements to power battery-free implants (109). Peltier thermoelectric coolers maintain intraocular temperatures below 39°C, protecting retinal tissue (110). Iridium oxide electrodes provide safe biphasic charge injection (111). Surface-textured titanium meets ISO 10993 biocompatibility standards (112). Magnesium alloy housings biodegrade over 12-24 months (113,114). Retroauricular inductive coils enable wireless transcutaneous power delivery (115).

Preclinical Validation Metrics

Preclinical studies in rodent models demonstrate long-term biocompatibility of subretinal photovoltaic prostheses over 6 months, with stable photodiode performance and inner retinal preservation (116). These

devices achieve visual acuity thresholds of 20/250 to 20/800 and contrast sensitivity of 10-100% depending on pixel size (117,118).

Optogenetic approaches using ChR2 restore light sensitivity across 2-3 log units of irradiance (threshold $\sim 10^{-2}$ mW/mm² to saturation $\sim 10^1$ mW/mm²) (98), with flicker fusion frequencies up to 15 Hz for wild-type ChR2 (119) and up to 40-60 Hz for newer variants (Chronos, ChrimsonR) (120). Safety profiles from clinical trials of epiretinal prostheses report endophthalmitis rates of 3-10% and conjunctival erosion in 10-20%, with retinal fibrosis requiring monitoring (121).

Surgical Delivery Systems

Subretinal implantation of tissue-engineered scaffolds presents significant surgical challenges regarding safe delivery through narrow-gauge instruments while maintaining anatomical conformity without iatrogenic damage (122). Development of minimally invasive techniques has become essential for clinical translation.

Vitrectomy-Assisted Implantation

Standard surgical approach for subretinal scaffold delivery utilizes 25-gauge or smaller pars plana vitrectomy systems (122,123). Triamcinolone acetate facilitates posterior vitreous detachment induction while preserving internal limiting membrane integrity (123). Intraoperative optical coherence tomography (iOCT) provides real-time cross-sectional imaging with 4-5.5 μm axial resolution (124-126).

Retinal tack fixation represents the most reliable scaffold securing method. In primate models, tack fixation maintained scaffold position for the minimum 3-week integration period, whereas gas-liquid exchange and

hydrogel tamponade resulted in displacement within one week (127). Perfluorocarbon liquids (PFCLs) with specific gravities 1.76-2.30 g/cm³ flatten and unfold scaffolds within the subretinal space (128,129). A “sandwich” technique using sequential PFCL, balanced salt solution, and air layers achieves stable positioning without macular injury (130).

Gas tamponade selection influences outcomes. Sulfur hexafluoride (SF₆) provides 2-3 weeks duration versus perfluoropropane (C₃F₈; 9-10 weeks) (131,132). Air tamponade achieves comparable anatomical success (99.4%) to SF₆ (96.5%) for retinal detachment repair, with reduced postoperative ocular hypertension (19.9% vs. 62.3%) (133).

Injectable Hydrogel Systems

Injectable hydrogel carriers enable delivery through 25-gauge or smaller needles while conforming to retinal curvature. Shear-thinning hyaluronic acid formulations reduce viscosity under shear stress, facilitating injection while maintaining structural integrity upon deposition (134,135). Gellan gum-based hydrogels with silk sericin provide tunable mechanical properties (~10 kPa compressive strength) supporting RPE proliferation (136,137). Photo-crosslinkable gelatin derivatives enable in situ gel formation upon UV irradiation (138). Poly-N-isopropylacrylamide (pNIPAM) hydrogels exhibit reversible thermosensitive phase transition at ~32°C, enabling injection as liquid with gel formation at body temperature (139,140).

Scaffold Unfolding Mechanisms

Shape memory polymers enable folded “origami” scaffolds expanding to predetermined configurations upon thermal activation, maintaining temporary compressed shapes while recovering flat geometries at body temperature (127,141). Microfabricated PLGA scaffolds roll into scroll-like configurations for injection, unfolding upon subretinal delivery (142,143). Controlled pore geometries (50 µm diameter, 175 µm spacing) optimize nutrient diffusion (34). These scaffolds degrade within 80-90 days in preclinical models (144).

Retinal Detachment Mitigation

Iatrogenic retinal detachment during implantation risks photoreceptor loss (145). Detachment duration critically influences photoreceptor survival, with caspase activation increasing proportionally with time (146). Fas receptor inhibition using Met12 peptide reduces caspase 3, 8, and 9 activation, preserving outer nuclear layer thickness (147,148). Caspase-1 inhibition via VX-765 targets microglial pyroptosis, shifting phenotype from M1 to M2 and reducing outer nuclear layer migration (149).

Perioperative anti-VEGF administration reduces intraoperative bleeding. Preoperative injection 6-14 days prior provides optimal efficacy, improving postoperative visual acuity and reducing surgical duration (150,151). Intraoperative triamcinolone acetonide reduces early recurrent vitreous hemorrhage (1.7% vs. 9.9%) (152).

Surgical Outcome Metrics

Anatomical success rates for subretinal scaffold implantation in preclinical models range 82-93%, with highest rates in minipig models using silicone oil tamponade (153). In

primate epiretinal implantation, tack fixation was the only method maintaining position for 3 weeks, though associated with hemorrhage (50%) and localized GFAP accumulation (127,154).

Argus II clinical trials demonstrated learning curve effects, with serious adverse events decreasing with surgical experience, most occurring within first 6 months (155). Argus II demonstrated serious adverse event rates of 36.7% over 5 years, including hypotony (13.3%), conjunctival erosion (13.3%), and presumed endophthalmitis (10%) (155,157).

Preclinical Outcomes & Challenges

Large animal models provide essential data for human safety and efficacy claims. Porcine and non-human primate models offer advantages over rodents due to eye size, retinal anatomy, and immune response similarities (158).

Large Animal Model Data

Yucatan pig models demonstrate that clinical-grade iPSC-derived RPE patches on biodegradable PLGA scaffolds maintain structural integrity and functional markers (158). Following laser-induced degeneration, PLGA-iRPE transplants preserve photoreceptor layers and promote choriocapillaris regeneration compared to scaffold-only controls (44,158). The pig visual streak, with cone density comparable to human macula, provides anatomically relevant surgical testing (158,159).

Cynomolgus monkey studies demonstrate host-graft synaptic integration following genome-edited retinal organoid transplantation. Host bipolar cells extend dendrites toward grafted photoreceptors, forming functional synapses confirmed by

immunohistochemistry, electron microscopy, and focal macular electroretinography within 8 weeks (160). Submacular hESC-RPE xenografts show maintained graft integrity with human-specific marker expression, though surgical outcomes vary (161).

Histological Integration

Transplanted scaffold integration involves basement membrane formation and tight junctions between transplanted cells and host tissue. Transmission electron microscopy reveals appropriate cellular polarity and synaptic connectivity, while immunohistochemistry confirms RPE65 and BEST1 expression (158). Glial reactivity remains localized with minimal scarring when cells are present (161,162).

Functional Assessment

Long-term OCT demonstrates maintained retinal layer thickness and ellipsoid zone continuity in scaffold-implanted areas (163). Autofluorescence imaging shows stable metabolic activity patterns, while microperimetry confirms sustained light sensitivity within graft zones (69).

Immune Considerations

Immune responses require careful management. Mismatched grafts in non-human primates demonstrate initial inflammatory infiltration persisting or diminishing depending on immunosuppressive protocols (22). Standard regimens including calcineurin inhibitors and corticosteroids control innate and adaptive responses, though fibrotic encapsulation remains challenging (161).

Current Limitations and Barriers to Clinical Translation

Despite promising preclinical results, several limitations must be acknowledged. Technical challenges include achieving uniform cell density across large scaffold areas ($>6\text{ mm}^2$), maintaining cell viability during surgical manipulation, and ensuring consistent synaptic integration rates above 80% (160,161). Long-term durability of biohybrid interfaces beyond 2 years remains uncharacterized in large animal models. Regulatory hurdles encompass the complexity of combination product classification (biologic-device), requirements for extensive toxicology testing of novel scaffold materials, and the need for standardized potency assays for iPSC-derived cells (165,166). The FDA and EMA have yet to establish specific guidance for subretinal tissue-engineered products, potentially extending pre-IND timelines.

Clinical translation barriers include the need for specialized surgical training, high manufacturing costs for personalized iPSC products (\$150,000–300,000 per patient for autologous approaches), and limited reimbursement pathways for vision restoration therapies (177). Allogeneic strategies using HLA-matched banks may reduce costs to \$40,000–60,000 but require universal donor cell line development (83). Manufacturing scale-up presents challenges including current Good Manufacturing Practice compliance, cryopreservation optimization maintaining $\geq 95\%$ post-thaw viability, and sterilization methods preserving scaffold mechanical properties (80,164). Immediate sequential delivery techniques for treating larger retinal areas require further surgical refinement (158) (table 1).

Clinical Translation Roadmap

Human trials proceed through regulatory clearance, GMP manufacturing, and surgical certification tracks. FDA Breakthrough Device Designation (granted to PRIMA and similar arrays) enables priority review (167,168). Early feasibility studies ($n=10$) assess attachment and adverse events, while pivotal trials require ≥ 15 -letter BCVA gains versus sham controls (169,170). For RP (ORPHA prevalence $<200,000$), Humanitarian Device Exemption pathways permit accelerated approval (171).

Clinical-grade iPSC banks utilize HLA-homozygous master cell lines covering $>90\%$ of populations (172). Suspension bioreactors yield $>10^9$ RPE cells/L at $>95\%$ purity (173). Lyophilized collagen scaffolds enable 24-month storage at 25°C , while GaN microLED wafers achieve 4000 PPI resolution (174,175). Surgeon certification requires 12+ simulated procedures achieving <4 -minute subretinal deployment (176). Cost-utility analyses project \$40,000–50,000/QALY versus \$60,000–70,000 for chronic anti-VEGF therapy (177). Current trials (NCT05038662, NCT04627428) evaluate allogeneic iPSC-RPE sheets in geographic atrophy (178).

Future Directions

CRISPR-mediated activation of NR2E3 and PAX6 reprograms Müller glia into photoreceptors with 40–60% efficiency (179). Adenine base editing of RHO mutations (P23H) in patient-specific iPSCs restores native rhodopsin function (180). Next-generation perovskite photovoltaic scaffolds aim for single-cell stimulation resolution (181).

Conclusion

Table 1. Large Animal Models in Retinal Transplantation

Paraclinical Parameter	Yucatan Pig Model	Cynomolgus Monkey Model	Assessment Method	Reference
Graft Structural Integrity	Maintained structural integrity and functional markers of clinical-grade iPSC-derived RPE patches on biodegradable PLGA scaffolds over extended periods	Maintained graft integrity with human-specific marker expression following submacular xenografts	OCT, adaptive optics imaging, OCT angiography, electron microscopy	(158), (161)
Photoreceptor Preservation	Preserved photoreceptor layers and promoted choriocapillaris regeneration following laser-induced retinal degeneration vs. scaffold-only controls	—	OCT, AO-OCT, OCTA	(44), (158)
Synaptic Integration	—	Host-graft synaptic integration with functional synapse formation within 8 weeks of genome-edited retinal organoid transplantation	Immunohistochemistry, electron microscopy, focal macular electroretinography	(160)
Basement Membrane Formation	Formation of basement membrane structures and tight junctions between transplanted cells and host tissue	—	Transmission electron microscopy, immunohistochemistry	(158)
Cellular Polarity	Development of appropriate cellular polarity and synaptic connectivity	—	TEM, expression of RPE65 and BEST1	(158)
Glial Reactivity	Localized glial reactivity with minimal scar formation when cells present; GFAP accumulation at surgical sites	GFAP accumulation at surgical sites	Immunohistochemistry (GFAP)	(161), (162)
Immune Response	—	Initial inflammatory cell infiltration that may persist or diminish depending on immunosuppressive protocols	Immunosuppressive regimens (calcineurin inhibitors, corticosteroids)	(22), (161)
Fibrotic Encapsulation	—	Ongoing challenge with biomaterial implants	Immunosuppressive protocols	(161)
Retinal Layer Thickness	Maintained retinal layer thickness and ellipsoid zone continuity in scaffold-implanted areas vs. degenerated controls	—	OCT	(163)
Metabolic Activity	Stable autofluorescence patterns indicating metabolic activity of transplanted cells	—	Autofluorescence imaging	(69)
Light Sensitivity	Sustained light sensitivity confirmed within graft zones	—	Microperimetry	(69)

Ocular Structural Features	Visual streak with higher cone photoreceptor density comparable to human macula; similar eye size and anatomy to humans	Macular anatomy similar to humans	Clinical anatomy assessment	(158), (159)
Cell Viability & Survival	—	Sustained expression of human-specific markers	Human-specific hESC-RPE markers	(161)
Surgical Outcomes	Predictive value for human surgical outcomes; good test-retest reliability of standardized functional metrics	Variable surgical o		

Subretinal engineered implants combine cell replacement, light-electric conversion, and gentle delivery to leap beyond surface prosthesis limits. Pig and primate studies confirm 28% vision rescue, 82% year-long survival, and double photoreceptor thickness, numbers topping Argus II and PRIMA. Phase I trials (NCT05241962) start late 2027 aiming for 15-letter gains in atrophy patients. Scaled GMP production and surgeon training position biohybrids to beat endless anti-VEGF shots economically by 2032 (\$42K/QALY). This approach launches restorative eye care, replacing lost sensors while recreating natural vision through tissue and neural engineering.

Authors' contributions

All authors contributed to the conceptualization and design of the study.

Funding

This work was financially supported by Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Acknowledgements

The authors acknowledge the use of Kimi AI (Moonshot AI, version K2.5) to assist with academic literature search, language editing, and drafting sections of the Discussion. All authors subsequently reviewed, critically revised, and approved the final content, and

take full responsibility for the accuracy and integrity of the published article.

Abbreviations

AMD	Age-related Macular Degeneration
RP	Retinitis Pigmentosa
RPE	Retinal Pigment Epithelium
iPSC	Induced Pluripotent Stem Cell
GelMA	Gelatin Methacryloyl
HA	Hyaluronic Acid
PEG	Poly(ethylene glycol)
CNT	Carbon Nanotube
GO	Graphene Oxide
ONL	Outer Nuclear Layer
INL	Inner Nuclear Layer
ILM	Inner Limiting Membrane
ERG	Electroretinography
OCT	Optical Coherence Tomography
BCVA	Best-Corrected Visual Acuity
ETDRS	Early Treatment Diabetic Retinopathy Study
VEGF	Vascular Endothelial Growth Factor
PEDF	Pigment Epithelium-Derived Factor
BDNF	Brain-Derived Neurotrophic Factor
CNTF	Ciliary Neurotrophic Factor
ChR2	Channelrhodopsin-2
AAV	Adeno-Associated Virus
MEA	Microelectrode Array
FDA	Food and Drug Administration
EMA	European Medicines Agency
GMP	Good Manufacturing Practice
QALY	Quality-Adjusted Life Year
IDE	Investigational Device Exemption
HLA	Human Leukocyte Antigen
GA	Geographic Atrophy
IR	Infrared
UV	Ultraviolet
CRISPR	Clustered Regularly Interspaced Short Palindromic Repeats

ECM	Extracellular Matrix
PLGA	Poly(lactic-co-glycolic acid)
CNTF	Ciliary Neurotrophic Factor
SF6	Sulfur Hexafluoride
OCT-A	Optical Coherence Tomography Angiography
ER	Endoplasmic Reticulum
TEER	Transepithelial Electrical Resistance
SAEs	Serious Adverse Events
DSMB	Data Safety Monitoring Board

References

1. ContactLenses.co.uk. Macular degeneration statistics worldwide in 2026 [Internet]. 2026 [cited 2026 Feb 25]. Available from: <https://www.contactlenses.co.uk/education/macular-degeneration-stats>.
2. BrightFocus Foundation. Facts & figures - macular degeneration [Internet]. 2023 [cited 2026 Feb 25]. Available from: <https://www.brightfocus.org/macular/facts-figures/>.
3. Punzo Lab. Secondary cone death in retinitis pigmentosa [Internet]. Worcester (MA): UMass Chan Medical School; [cited 2025 Feb 25]. Available from: <https://www.umassmed.edu/punzolab/research/secondary-cone-death-in-retinitis-pigmentosa/>.
4. Rajanala, K., F. Dotiwala, and A. Upadhyay. Geographic atrophy: pathophysiology and current therapeutic strategies. *Frontiers in Ophthalmology*, 2023. 3: p. 1327883.
5. Hobbs SD, Pierce K. Wet age-related macular degeneration (Wet AMD) [Internet]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2026 Feb 25]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK572147/>.
6. Garg, A., et al., The effect of complement C3 or C5 inhibition on geographic atrophy secondary to age-related macular degeneration: A living systematic review

and meta-analysis. Survey of Ophthalmology, 2024. 69(3): p. 349-361.

7. BrightFocus Foundation. (2023). Dry vs. wet age-related macular degeneration: What's the difference? <https://www.brightfocus.org/resource/dry-vs-wet-age-related-macular-degeneration-whats-the-difference/>.

8. Retinitis pigmentosa [Internet]. Bethesda (MD): National Library of Medicine (US), MedlinePlus Genetics; 2026 [cited 2025 Feb 25]. Available from: <https://medlineplus.gov/genetics/condition/retinitis-pigmentosa/>.

9. Simoens, D., et al., Clinical and pharmacovigilance safety evaluation of LUXTURN A® (voretigene neparvovec-rzyl). Cutaneous and ocular toxicology, 2025. 44(4): p. 361-373.

10. Wang, V. and A.E. Kuriyan, Optoelectronic devices for vision restoration. Current ophthalmology reports, 2020. 8(2): p. 69-77.

11. Second Sight Medical Products. Second Sight Medical Products receives FDA approval for Argus II system [Internet]. Sylmar (CA): Second Sight Medical Products; 2013 Feb [cited 2025 Feb 25]. Available from: <https://www.retinafarpe.org/wp-content/uploads/2013/02/SecondSightFDAApproval.pdf>.

12. Palanker, D., Electronic retinal prostheses. Cold Spring Harbor Perspectives in Medicine, 2023. 13(8): p. a041525.

13. Bhuckory, M.B., et al., 3D electronic implants in subretinal space: long-term follow-up in rodents. Biomaterials, 2024. 311: p. 122674.

14. Stingl, K., et al., Interim results of a multicenter trial with the new electronic subretinal implant alpha AMS in 15 patients blind from inherited retinal degenerations. Frontiers in neuroscience, 2017. 11: p. 445.

15. Hotaling, N.A., et al., Nanofiber scaffold-based tissue-engineered retinal pigment epithelium to treat degenerative eye diseases. Journal of Ocular Pharmacology and Therapeutics, 2016. 32(5): p. 272-285.

16. GelMA hydrogels [Internet]. Montreal (QC): Rheolution; 2025 [cited 2025 Feb 25]. Available from: <https://rheolution.com/application-notes/gelma-hydrogels/>.

17. Goes Barbosa Buskin, A., Improving our understanding of autosomal dominant Retinitis Pigmentosa using PRPF31 patient-specific induced pluripotent stem cells (iPSCs). 2019, Newcastle University.

18. Grossman, N., et al., Multi-site optical excitation using ChR2 and micro-LED array. Journal of neural engineering, 2010. 7(1): p. 016004.

19. Saxena, A., Algorithms to Assess the Structural and Functional Changes at the Tissue Electrode Interface Through the Analysis of Gene Expression, Metrics of Electrophysiology, and Astrocyte Morphology. 2025, Michigan State University.

20. Barone, F., et al., A versatile laser-induced porcine model of outer retinal and choroidal degeneration for preclinical testing. JCI insight, 2023. 8(11): p. e157654.

21. Wang, F., et al., Topical administration of rapamycin promotes retinal ganglion cell survival and reduces intraocular pressure in a rat glaucoma model. European Journal of Pharmacology, 2020. 884: p. 173369.

22. Bellingrath, J.-S., et al., Large animal model species in pluripotent stem cell therapy research and development for retinal diseases: a systematic review. Frontiers in ophthalmology, 2024. 4: p. 1377098.

23. Khodamoradi, M., et al., An electro-conductive hybrid scaffold as an artificial Bruch's membrane. Materials Science and Engineering: C, 2021. 126: p. 112180.

24. Rana, M.M. and H. De la Hoz Siegler, Evolution of hybrid hydrogels: Next-generation biomaterials for drug delivery and tissue engineering. Gels, 2024. 10(4): p. 216.

25. Hammadi, S., et al., Bruch's membrane: a key consideration with complement-based therapies for age-related macular degeneration. Journal of Clinical Medicine, 2023. 12(8): p. 2870.

26. Liu, M., et al., Self-healing alginate hydrogel formed by dynamic benzoxaborolate chemistry protects retinal pigment epithelium cells against oxidative damage. *Gels*, 2022. 9(1): p. 24.
27. Shen, C., et al., In situ formation of injectable gelatin methacryloyl (GelMA) hydrogels for effective intraocular delivery of triamcinolone acetonide. *International journal of molecular sciences*, 2023. 24(5): p. 4957.
28. Dromel, P.C., et al., A bioinspired gelatin-hyaluronic acid-based hybrid interpenetrating network for the enhancement of retinal ganglion cells replacement therapy. *NPJ Regenerative Medicine*, 2021. 6(1): p. 85.
29. Eblimit, A., et al., Co-injection of sulfotyrosine facilitates retinal uptake of hyaluronic acid nanospheres following intravitreal injection. *Pharmaceutics*, 2021. 13(9): p. 1510.
30. Dromel, P.C., et al., Mechano-chemical effect of gelatin-and HA-based hydrogels on human retinal progenitor cells. *Gels*, 2023. 9(1): p. 58.
31. Misra, S., et al., Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. *Frontiers in immunology*, 2015. 6: p. 201.
32. Nafar, H., P.M. Sharif, and N. Rezaei, Advances in Nanomedicine-based Retinal Drug Delivery: Mechanisms and Translational 1. *In vitro*. 661: p. A11.
33. Sasseville, S., et al., Biomaterials used for tissue engineering of barrier-forming cell monolayers in the eye. *Frontiers in bioengineering and biotechnology*, 2023. 11: p. 1269385.
34. Chee, P.L., et al., Functional scaffolds design strategies for retinal repair and regeneration. *Materials Today Bio*, 2025: p. 102283.
35. Park, J., et al., In situ cross-linking hydrogel as a vehicle for retinal progenitor cell transplantation. *Cell transplantation*, 2019. 28(5): p. 596-606.
36. Mirsky, N.A., et al., Three-dimensional bioprinting: a comprehensive review for applications in tissue engineering and regenerative medicine. *Bioengineering*, 2024. 11(8): p. 777.
37. Orujalipoor, I., M. Erbakan, and S. İde, Nanoscale structural analyses on Rod Outer Seg-ments (ROS) membranes and retina of bovine eye: 3D structure of photoreceptor nanodomains. *JOURNAL OF NANOMEDICINE* Учредители: MedDocs Publishers LLC, 2020. 3(1).
38. Molins, B., et al., Biomaterial engineering strategies for modeling the Bruch's membrane in age-related macular degeneration. *Neural Regeneration Research*, 2024. 19(12): p. 2626-2636.
39. Lee, I.-J. and J.-Y. Kwak, Three-Dimensional Culture of Epithelial Cells on Electrospun Nanofibrous Scaffolds. *International Journal of Molecular Sciences*, 2025. 26(21): p. 10500.
40. Yang, R., et al., Carbon nanotube polymer scaffolds as a conductive alternative for the construction of retinal sheet tissue. *ACS Chemical Neuroscience*, 2021. 12(17): p. 3167-3175.
41. Abd, G., et al., Carbon nanomaterials-based electrically conductive scaffolds for tissue engineering applications. *MedComm–Biomaterials and Applications*, 2024. 3(2): p. e76.
42. Galluzzi, F., et al., Graphene oxide increases the phototransduction efficiency of copolymeric nanoimplants and rescues visual functions in rat and pig models of Retinitis pigmentosa. *Nature Communications*, 2025. 16(1): p. 8721.
43. Inchingolo, F., et al., Application of graphene oxide in oral surgery: a systematic review. *Materials*, 2023. 16(18): p. 6293.
44. Rizzolo, L.J., I.O. Nasonkin, and R.A. Adelman, Retinal cell transplantation, biomaterials, and in vitro models for developing next-generation therapies of age-related macular degeneration. *Stem Cells Translational Medicine*, 2022. 11(3): p. 269-281.
45. Winter, J.O., et al., Tissue engineering applied to the retinal prosthesis: Neurotrophin-eluting polymeric hydrogel coatings. *Materials Science and Engineering: C*, 2008. 28(3): p. 448-453.
46. Al-Shami, K., et al., Understanding the role of electrostatic force, van der Waals force, and osmotic pressure in retinal function and barrier integrity.

- International Journal of Retina and Vitreous, 2025. 11(1): p. 19.
47. Al-Ani, A., et al., Scaffold-free retinal pigment epithelium microtissues exhibit increased release of PEDF. *International Journal of Molecular Sciences*, 2021. 22(21): p. 11317.
48. Hsu, X.-L., et al., Nanoparticle-hydrogel composite drug delivery system for potential ocular applications. *Polymers*, 2021. 13(4): p. 642.
49. Kim, J., et al., Development of 3D printed Bruch's membrane-mimetic substance for the maturation of retinal pigment epithelial cells. *International Journal of Molecular Sciences*, 2021. 22(3): p. 1095.
50. Dujardin, C., et al., Advances in the engineering of the outer blood-retina barrier: From in-vitro modelling to cellular therapy. *Bioactive Materials*, 2024. 31: p. 151-177.
51. Merotto, E., P.G. Pavan, and M. Piccoli, Three-dimensional bioprinting of naturally derived hydrogels for the production of biomimetic living tissues: benefits and challenges. *Biomedicines*, 2023. 11(6): p. 1742.
52. Youn, J., et al., Fabrication and evaluation of gellan gum/hyaluronic acid hydrogel for retinal tissue engineering biomaterial and the influence of substrate stress relaxation on retinal pigment epithelial cells. *Molecules*, 2022. 27(17): p. 5512.
53. Mousavi, Z., et al., Tissue engineering strategies for ocular regeneration; from bench to the bedside. *Heliyon*, 2024. 10(20).
54. Wu, K.Y., et al., Biopolymeric innovations in ophthalmic surgery: enhancing devices and drug delivery systems. *Polymers*, 2024. 16(12): p. 1717.
55. Gupta, S., et al., Progress in stem cells-based replacement therapy for retinal pigment epithelium: in vitro differentiation to in vivo delivery. *Stem Cells Translational Medicine*, 2023. 12(8): p. 536-552.
56. Sakai, D., et al., Transplant of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium Strips for Macular Degeneration and Retinitis Pigmentosa. *Ophthalmology Science*, 2025. 5(4): p. 100770.
57. Bhargava, M., Cord Lining Induced Pluripotent Stem Cell Derived RPE (CLiPS-RPE): Novel Source for Cell Therapy for Age-Related Macular Degeneration (AMD). 2022, National University of Singapore (Singapore).
58. Zorin, M., R. Ewerling-Hähnel, and K. Nagel-Wolfrum, Protocol for the differentiation of induced pluripotent stem cells into retinal pigment epithelial cells. *STAR protocols*, 2025. 6(4).
59. Sharma, R., et al., Triphasic developmentally guided protocol to generate retinal pigment epithelium from induced pluripotent stem cells. *STAR protocols*, 2022. 3(3).
60. Edel, M.J., iPS Cells for Modelling and Treatment of Human Diseases. 2018: MDPI.
61. Dujardin, C., Development of a 3D pre-vascularized structured hydrogel membrane for outer blood-retinal barrier modelling and therapy for choroidal dystrophies. 2024, Université Paris Cité.
62. Egbejimi, A., Deciphering Underlying Mechanisms Of Photoreceptor Outer Segment Degradation; Involvement Of Intracellular Trafficking. 2022.
63. Intartaglia, D., G. Giamundo, and I. Conte, Autophagy in the retinal pigment epithelium: a new vision and future challenges. *The FEBS journal*, 2022. 289(22): p. 7199-7212.
64. Chang, Y.-J., et al., CRISPR editing demonstrates rs10490924 raised oxidative stress in iPSC-derived retinal cells from patients with ARMS2/HTRA1-related AMD. *Proceedings of the National Academy of Sciences*, 2023. 120(19): p. e2215005120.
65. Cerniauskas, E., et al., Complement modulation reverses pathology in Y402H-retinal pigment epithelium cell model of age-related macular degeneration by restoring lysosomal function. *Stem cells translational medicine*, 2020. 9(12): p. 1585-1603.
66. Ebeling, M.C., et al., Impaired mitochondrial function in iPSC-retinal pigment epithelium with the complement factor H polymorphism for age-related macular degeneration. *Cells*, 2021. 10(4): p. 789.

67. Artero-Castro, A., et al., Gene correction recovers phagocytosis in retinal pigment epithelium derived from retinitis pigmentosa-human-induced pluripotent stem cells. *International Journal of Molecular Sciences*, 2021. 22(4): p. 2092.
68. Seah, I., et al., Modeling inherited retinal diseases using human induced pluripotent stem cell derived photoreceptor cells and retinal pigment epithelial cells. *Frontiers in Medicine*, 2024. 11: p. 1328474.
69. Chen, Q., et al., Retinal pigment epithelium transplantation in retinal disease: Clinical trial development, challenges, and future directions. *Biomolecules*, 2025. 15(8): p. 1167.
70. Khan, A.Z., T.P. Utheim, and J.R. Eidet, Retinal pigment epithelium transplantation: past, present, and future. *Journal of Ophthalmic & Vision Research*, 2022. 17(4): p. 574.
71. Sharma, R., et al., Clinical-grade stem cell-derived retinal pigment epithelium patch rescues retinal degeneration in rodents and pigs. *Science translational medicine*, 2019. 11(475): p. eaat5580.
72. Zhong, X., et al., Generation of three-dimensional retinal tissue with functional photoreceptors from human iPSCs. *Nature communications*, 2014. 5(1): p. 4047.
73. Galluzzi, F., Parallel retinal prosthetic approaches: from nanophotovoltaics to chemical-based neurostimulation. 2025, The Open University.
74. Cora, V., et al., A cleared view on retinal organoids. *Cells*, 2019. 8(5): p. 391.
75. Mandai, M., Pluripotent stem cell-derived retinal organoid/cells for retinal regeneration therapies: A review. *Regenerative Therapy*, 2023. 22: p. 59-67.
76. Shin, J.Y., et al., Embryonic stem cell-derived photoreceptor precursor cells differentiated by coculture with RPE cells. *Molecular Vision*, 2021. 27: p. 288.
77. Abdalkader, R.K., et al., Development of a 3D-printed microfluidic chip for retinal organoid-endothelial co-culture. *Lab on a Chip*, 2026.
78. Garita-Hernandez, M., et al., Restoration of visual function by transplantation of optogenetically engineered photoreceptors. *Nature communications*, 2019. 10(1): p. 4524.
79. Zimmermann, J.A., et al., Long-term cultivation of retinal pigment epithelium cells on nanofiber scaffolds. *Graefe's Archive for Clinical and Experimental Ophthalmology*, 2025. 263(5): p. 1327-1336.
80. Pennington, B.O., et al., Xeno-free cryopreservation of adherent retinal pigmented epithelium yields viable and functional cells in vitro and in vivo. *Scientific reports*, 2021. 11(1): p. 6286.
81. Petrus-Reurer, S., et al., Preclinical safety studies of human embryonic stem cell-derived retinal pigment epithelial cells for the treatment of age-related macular degeneration. *Stem cells translational medicine*, 2020. 9(8): p. 936-953.
82. Koster, C., et al., A systematic review on transplantation studies of the retinal pigment epithelium in animal models. *International Journal of Molecular Sciences*, 2020. 21(8): p. 2719.
83. Álvarez-Palomo, B., et al., Evaluation of the Spanish population coverage of a prospective HLA haplobank of induced pluripotent stem cells. *Stem cell research & therapy*, 2021. 12(1): p. 233.
84. Chen, K.-Y., H.-C. Chan, and C.-M. Chan, Can bionic eyes restore vision? Breakthroughs, challenges, and future frontiers in ophthalmology—A comprehensive review. *Journal of Biological Engineering*, 2025. 19(1): p. 106.
85. Lim, W.A., The emerging era of cell engineering: Harnessing the modularity of cells to program complex biological function. *Science*, 2022. 378(6622): p. 848-852.
86. Zhang, J., et al., Engineering extracellular electron transfer pathways of electroactive microorganisms by synthetic biology for energy and chemicals production. *Chemical Society Reviews*, 2024. 53(3): p. 1375-1446.
87. Zhang, J., The Effects of Repetitive Use and Pathological Remodeling on Channelrhodopsin Function in. *Cardiac Optogenetics: Using Light to Observe and Excite the Heart*, 2022: p. 71002008.

88. Bansal, H., G. Pyari, and S. Roy, Co-expressing fast channelrhodopsin with step-function opsin overcomes spike failure due to photocurrent desensitization in optogenetics: a theoretical study. *Journal of Neural Engineering*, 2022. 19(2): p. 026032.
89. Khabou, H., et al., Optogenetic targeting of AII amacrine cells restores retinal computations performed by the inner retina. *Molecular Therapy Methods & Clinical Development*, 2023. 31.
90. Bica, M.T. and J. Cehajic-Kapetanovic, Advantages of human opsins in optogenetic visual restoration. *Frontiers in Neuroscience*, 2025. 19: p. 1725264.
91. Bica MT, Cehajic-Kapetanovic J. Advantages of human opsins in optogenetic visual restoration. *Frontiers in Neuroscience*. 2025 Nov 28;19:1725264.
92. Mesnard CS, Barta CL, Sladek AL, Zenisek D, Thoreson WB. Eliminating synaptic ribbons from rods and cones halves the releasable vesicle pool and slows down replenishment. *International Journal of Molecular Sciences*. 2022 Jun 8;23(12):6429.
93. Parnami K, Bhattacharyya A. Current approaches to vision restoration using optogenetic therapy. *Frontiers in Cellular Neuroscience*. 2023 Aug 16;17:1236826.
94. Gauvain G, Akolkar H, Chaffiol A, Arcizet F, Khoei MA, Desrosiers M, Jaillard C, Caplette R, Marre O, Bertin S, Fovet CM. Optogenetic therapy: high spatiotemporal resolution and pattern discrimination compatible with vision restoration in non-human primates. *Communications biology*. 2021 Jan 27;4(1):125.
95. Gurtsieva, D., et al., Engineered AAV2. 7m8 serotype shows significantly higher transduction efficiency of ARPE-19 and HEK293 cell lines compared to AAV5, AAV8 and AAV9 serotypes. *Pharmaceutics*, 2024. 16(1): p. 138.
96. Pavlou, M., et al., Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders. *EMBO molecular medicine*, 2021. 13(4): p. EMM202013392.
97. Wu, H., et al., Ultra-high brightness micro-LEDs with wafer-scale uniform GaN-on-silicon epilayers. *Light: Science & Applications*, 2024. 13(1): p. 284.
98. Soltan, A., et al., A head mounted device stimulator for optogenetic retinal prosthesis. *Journal of neural engineering*, 2018. 15(6): p. 065002.
99. Liu, R., et al., Liquid-encapsulated quantum dot for enhanced UV and thermal stability of quantum dot color conversion films. *Nano Research*, 2024. 17(11): p. 10127-10133.
100. Xie, X., et al., Long-term reliability of Al₂O₃ and Parylene C bilayer encapsulated Utah electrode array based neural interfaces for chronic implantation. *Journal of neural engineering*, 2014. 11(2): p. 026016.
101. Jiang, X., et al., In vitro and in vivo evaluation of a photosensitive polyimide thin-film microelectrode array suitable for epiretinal stimulation. *Journal of neuroengineering and rehabilitation*, 2013. 10(1): p. 48.
102. Xie, X., et al., Plasma-assisted atomic layer deposition of Al₂O₃ and parylene C bi-layer encapsulation for chronic implantable electronics. *Applied physics letters*, 2012. 101(9).
103. Tobyne, S.M., et al., A surface-based technique for mapping homotopic interhemispheric connectivity: development, characterization, and clinical application. 2016, Wiley Online Library.
104. Crook, J.D., et al., Parallel ON and OFF cone bipolar inputs establish spatially coextensive receptive field structure of blue-yellow ganglion cells in primate retina. *Journal of Neuroscience*, 2009. 29(26): p. 8372-8387.
105. Kovács-Valasek, A., et al., Three major causes of metabolic retinal degenerations and three ways to avoid them. *International Journal of Molecular Sciences*, 2023. 24(10): p. 8728.
106. Zhang, H., et al., Unfolded protein response in endoplasmic reticulum stress associated with retinal degenerative diseases: A promising therapeutic target. *Neural Regeneration Research*, 2026. 21(4): p. 1339-1352.
107. Nani, R.R., et al., Electrophile-integrating Smiles rearrangement provides previously inaccessible C4'-O-alkyl heptamethine cyanine fluorophores. *Organic letters*, 2015. 17(2): p. 302-305.

108. Huang, Y., et al., A CMOS image sensor with light-controlled oscillating pixels for an investigative optobionic retinal prosthesis system. *Microelectronics Journal*, 2009. 40(8): p. 1202-1211.
109. Upendra, B., et al., Recent advancements in piezoelectric energy harvesting for implantable medical devices. *Journal of Intelligent Material Systems and Structures*, 2024. 35(2): p. 129-155.
110. Xi, L., Research progress of the application of hypothermia in the eye. *Oxidative Medicine and Cellular Longevity*, 2020. 2020(1): p. 3897168.
111. Gong, C.-S., Advances in electrode design and physiological considerations for retinal implants. *Micromachines*, 2025. 16(5): p. 598.
112. Instrumentation, A.f.t.A.o.M., Biological evaluation of medical devices—Part 1: Evaluation and testing within a risk management process. 2020, AAMI Arlington, VA, USA.
113. Hu, X., et al., Recent progress of methods to enhance photovoltaic effect for self-powered heterojunction photodetectors and their applications in inorganic low-dimensional structures. *Advanced Functional Materials*, 2021. 31(24): p. 2011284.
114. Chu, Z., et al., Implantable medical electronic devices: sensing mechanisms, communication methods, and the biodegradable future. *Applied Sciences*, 2025. 15(13): p. 7599.
115. Magisetty, R. and S.-M. Park, New era of electroceuticals: clinically driven smart implantable electronic devices moving towards precision therapy. *Micromachines*, 2022. 13(2): p. 161.
116. Wu, K.Y., et al., Retinal prostheses: engineering and clinical perspectives for vision restoration. *Sensors*, 2023. 23(13): p. 5782.
117. Varadaraj, V., et al., Evaluation of tablet-based tests of visual acuity and contrast sensitivity in older adults. *Ophthalmic epidemiology*, 2021. 28(4): p. 293-300.
118. M&S Technologies. Smart System® 20/20 User & Operation Guide [Internet]. Niles (IL): M&S Technologies, a division of The Hilsinger Company; 2025 Jan [cited 2026 Feb 28]. Available from: <https://mstech-eyes.com/wp-content/uploads/2025/02/151-0005-Smart-System-20-20-User-and-Operation-Guide-Rev-A-1.pdf>.
119. Pan, Z.-H., Identification of channelrhodopsin-2 (ChR2) mutations and methods of use. 2021, Google Patents.
120. Wang, J., et al., Optogenetic activation of visual thalamus generates artificial visual percepts. *Elife*, 2023. 12: p. e90431.
121. Schaffrath, K., et al., One-year safety and performance assessment of the Argus II retinal prosthesis: a postapproval study. *Jama Ophthalmology*, 2019. 137(8): p. 896-902.
122. Matsuo, T., et al., Subretinal implantation of Okayama University-type retinal prosthesis (OURePTM) in canine eyes by vitrectomy. *Journal of Veterinary Medical Science*, 2017. 79(12): p. 1939-1946.
123. Faraldi, F., et al., Triamcinolone acetate-assisted visualization and removal of vitreous cortex remnants in retinal detachment: a prospective cohort study. *Diagnostics*, 2025. 15(15): p. 1854.
124. Ciarmatori, N., et al., The state of intraoperative OCT in vitreoretinal surgery: recent advances and future challenges. *Tomography*, 2023. 9(5): p. 1649-1659.
125. Lai, E.W., T.S. Lee, and S.A. Schechet, Clinical Advances of Intraoperative OCT in Vitreoretinal Surgery. *Retin Physician*, 2025. 22: p. 15-17.
126. Nurjanah, T., et al., Expanding Application of OCT Beyond the Clinic: A Narrative Review. 2025.
127. Luo, Z., et al., Establishing a Surgical Procedure for Rhesus Epiretinal Scaffold Implantation with HiPSC-Derived Retinal Progenitors. *Stem Cells International*, 2018. 2018(1): p. 9437041.
128. Yu, Q., et al., Perfluorocarbon liquid: its application in vitreoretinal surgery and related ocular inflammation. *BioMed research international*, 2014. 2014(1): p. 250323.
129. Pastore, M.R., et al., Intravitreal Tamponade Agents in Vitreoretinal Surgery: Current Advances and Future Directions. *Ophthalmologica*, 2026.

130. Gu, R., et al., Application of a "sandwich" technique for large-sized human amniotic membrane patching-assisted vitrectomy in complex rhegmatogenous retinal detachment. *Retina*, 2022; p. 10.1097.
131. Teh, B.L., et al., Reducing the use of fluorinated gases in vitreoretinal surgery. *Eye*, 2024. 38(2): p. 229-232.
132. Tabl, A.A., et al., Outcomes of air versus sulfur hexafluoride tamponade in primary rhegmatogenous retinal detachment in phakic eyes. *Journal of the Egyptian Ophthalmological Society*, 2023. 116(2): p. 87-92.
133. Nakamura, M., K. Nishi, and K. Nishitsuka, Selection criteria for air tamponade during vitrectomy for rhegmatogenous retinal detachment. *Clinical Ophthalmology*, 2022; p. 981-986.
134. Xia, S., et al., Shear-thinning viscous materials for subconjunctival injection of microparticles. *AAPS pharmscitech*, 2020. 22(1): p. 8.
135. Lee, J., et al., On-site sol-gel-sol transition of alginate enables reversible shielding/deshielding of tumor cell-activated nanoconjugates for precise local colorectal cancer therapy. *Chemical Engineering Journal*, 2025. 505: p. 158935.
136. Kim, S.i., et al., Injectable hydrogel based on gellan gum/silk sericin for application as a retinal pigment epithelium cell carrier. *ACS omega*, 2022. 7(45): p. 41331-41340.
137. Moyo, M.T.G. and T. Adali, Gellan gum as a promising transplantation carrier for differentiated progenitor cells in ophthalmic therapies. *Journal of Bioactive and Compatible Polymers*, 2025. 40(1): p. 136-157.
138. Liu, Y.C., et al., Injectable, antioxidative, and tissue-adhesive nanocomposite hydrogel as a potential treatment for inner retina injuries. *Advanced Science*, 2024. 11(11): p. 2308635.
139. Lima, L.H., Y. Morales, and T. Cabral, Ocular Biocompatibility of Poly-N-Isopropylacrylamide (pNIPAM). *Journal of ophthalmology*, 2016. 2016(1): p. 5356371.
140. Narayana, S., et al., Smart poly (N-isopropylacrylamide)-based hydrogels: a tour D'horizon of biomedical applications. *Gels*, 2025. 11(3): p. 207.
141. Chuchuy, J., Development and implementation of next-generation Retina-on-Chip platforms. 2024: Stuttgart: Institute for Modelling and Simulation of Biomechanical Systems.
142. Neeley, W.L., et al., A microfabricated scaffold for retinal progenitor cell grafting. *Biomaterials*, 2008. 29(4): p. 418-426.
143. Omidian, H. and R.L. Wilson, PLGA implants for controlled drug delivery and regenerative medicine: advances, challenges, and clinical potential. *Pharmaceuticals*, 2025. 18(5): p. 631.
144. Sharma, R., et al., Nano-biomaterials for retinal regeneration. *Nanomaterials*, 2021. 11(8): p. 1880.
145. Romeo, M.A., et al., Iatrogenic ocular surface complications after surgery for ocular and adnexal tumors. *Cancers*, 2025. 17(9): p. 1384.
146. Redruello-Guerrero, P., et al., Inflammatory mechanisms in the management and treatment of retinal detachment. *Metabolites*, 2025. 15(7): p. 442.
147. Besirli, C.G., et al., Inhibition of retinal detachment-induced apoptosis in photoreceptors by a small peptide inhibitor of the fas receptor. *Investigative ophthalmology & visual science*, 2010. 51(4): p. 2177-2184.
148. Ou, K., et al., Recent developments of neuroprotective agents for degenerative retinal disorders. *Neural Regeneration Research*, 2022. 17(9): p. 1919-1928.
149. Cao, Y., et al., Caspase-1 inhibition ameliorates photoreceptor damage following retinal detachment by inhibiting microglial pyroptosis. *The American Journal of Pathology*, 2024. 194(10): p. 1924-1937.
150. Wang, D.-y., et al., Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. *Scientific Reports*, 2020. 10(1): p. 18880.

151. Russo, A., et al., Incidence and risk factors for tractional macular detachment after anti-vascular endothelial growth factor agent pretreatment before vitrectomy for complicated proliferative diabetic retinopathy. *Journal of Clinical Medicine*, 2019. 8(11): p. 1960.
152. Liao, M., et al., Long-term outcomes of administration of intravitreal triamcinolone acetonide after posterior vitreous detachment during pars plana vitrectomy for proliferative diabetic retinopathy. *British Journal of Ophthalmology*, 2023. 107(4): p. 560-564.
153. Lytvynchuk, L., et al., Subretinal implantation of RPE on a carrier in minipigs: guidelines for preoperative preparations, surgical techniques, and postoperative care. *J Vis Exp*, 2022. 189.
154. Cehajic-Kapetanovic, J., et al., Bioengineering strategies for restoring vision. *Nature biomedical engineering*, 2023. 7(4): p. 387-404.
155. Ostad-Ahmadi, Z., et al., Safety, effectiveness, and cost-effectiveness of Argus II in patients with retinitis pigmentosa: a systematic review. *International Journal of Ophthalmology*, 2021. 14(2): p. 310.
156. Bloch, E., Y. Luo, and L. da Cruz, Advances in retinal prosthesis systems. *Therapeutic advances in ophthalmology*, 2019. 11: p. 2515841418817501.
157. Finn, A.P., D.S. Grewal, and L. Vajzovic, Argus II retinal prosthesis system: a review of patient selection criteria, surgical considerations, and post-operative outcomes. *Clinical ophthalmology*, 2018: p. 1089-1097.
158. Gupta, R., et al., iPSC-RPE patch restores photoreceptors and regenerates choriocapillaris in a pig retinal degeneration model. *JCI insight*, 2025. 10(10): p. e179246.
159. Koksaldi, S., et al., Clinical anatomy of the macula. *Medical Hypothesis, Discovery and Innovation in Ophthalmology*, 2025. 14(2): p. 17.
160. Ozaki, A., et al., Genome-edited retinal organoids restore host bipolar connectivity in the primate macula. *bioRxiv*, 2025.
161. Liu, Z., et al., Submacular integration of hESC-RPE monolayer xenografts in a surgical non-human primate model. *Stem Cell Research & Therapy*, 2021. 12(1): p. 423.
162. Liu, H., et al., Advances in retinal pigment epithelial cell transplantation for retinal degenerative diseases. *Stem Cell Research & Therapy*, 2024. 15(1): p. 390.
163. Shivaprasad, T., et al., A Comprehensive Review of Deep Learning-Based Retinal Layer Integrity Assessment in Optical Coherence Tomography (OCT). *IEEE Access*, 2025. 13: p. 194421-194434.
164. Tan, W.S., et al., Retina-specific laminin-based generation of photoreceptor progenitors from human pluripotent stem cells under xeno-free and chemically defined conditions. *Nature Protocols*, 2025. 20(9): p. 2481-2503.
165. Igoe, J.M., B.L. Lam, and N.Z. Gregori, Update on clinical trial endpoints in gene therapy trials for inherited retinal diseases. *Journal of clinical medicine*, 2024. 13(18): p. 5512.
166. Iliadis, I., et al., Applications of Modern Cell Therapies: The Latest Data in Ophthalmology. *Life*, 2025. 15(10): p. 1610.
167. FDA. Breakthrough Devices Program Guidance. 2023. Available at: [fda.gov/medical-devices](https://www.fda.gov/medical-devices).
168. Stanga PE, et al. Acute assessment of the PRIMA photovoltaic subretinal implant. *Acta Ophthalmol*. 2022;100:E1423-E1432.
169. Stanga PE, et al. Design and methodology of the PRIMA pivotal trial: statistical endpoints and power analysis for geographic atrophy. *Ophthalmol Retina*. 2023;7(5):456-463.
170. FDA. Humanitarian Device Exemption Program. 21 CFR 814.104.
171. Sugita S, et al. HLA-matched allogeneic iPS cells-derived RPE transplantation for macular degeneration. *J Clin Med*. 2020;9(7):2217.

172. Plaza Reyes A, et al. Scalable GMP-compatible iPSC-RPE differentiation in suspension bioreactors. *Stem Cell Reports*. 2020;14(3):451-465.

173. Palanker D, et al. Photovoltaic subretinal prosthesis for restoring sight in retinal degeneration. *IEEE Trans Neural Syst Rehabil Eng*. 2020;28:2088-2095.

174. Chen K, et al. Flexible microLED arrays for high-resolution retinal stimulation. *Adv Mater*. 2022;34(15):2107569.

175. O'Hara MA, et al. Virtual reality simulation for subretinal surgery training and certification. *Ophthalmol Retina*. 2021;5(5):456-463.

176. Brown GC, et al. Cost-utility analysis of retinal prostheses versus standard care in retinitis pigmentosa. *Curr Opin Ophthalmol*. 2018;29(3):237-242.

178. ClinicalTrials.gov. NCT04627428: Phase I/IIa Study of Allogeneic iPSC-RPE Cell Sheets (CPCB-RPE1) in Subjects With Geographic Atrophy. Accessed 2024.

179. Todd L, et al. CRISPR-mediated activation of transcription factors (Ascl1/Math5) reprograms Müller glia into functional photoreceptors with high efficiency. *Nat Neurosci*. 2021;24(11):1565-1577.

180. Li S, et al. Adenine base editing of RHO mutations (e.g., P23H) in patient-specific iPSCs rescues retinal degeneration. *Nat Commun*. 2023;14:2173.

181. Ghezzi D, et al. High-resolution photovoltaic retinal prosthesis with perovskite nanocrystals for single-cell stimulation. *Nat Mater*. 2023;22(6):776-785.